<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34852237</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>184</Volume><Issue>25</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>09</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>A defective viral genome strategy elicits broad protective immunity against respiratory viruses.</ArticleTitle><Pagination><StartPage>6037</StartPage><EndPage>6051.e14</EndPage><MedlinePgn>6037-6051.e14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2021.11.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(21)01338-6</ELocationID><Abstract><AbstractText>RNA viruses generate defective viral genomes (DVGs) that can interfere with replication of the parental wild-type virus. To examine their therapeutic potential, we created a DVG by deleting the capsid-coding region of poliovirus. Strikingly, intraperitoneal or intranasal administration of this genome, which we termed eTIP1, elicits an antiviral response, inhibits replication, and protects mice from several RNA viruses, including enteroviruses, influenza, and SARS-CoV-2. While eTIP1 replication following intranasal administration is limited to the nasal cavity, its antiviral action extends non-cell-autonomously to the lungs. eTIP1 broad-spectrum antiviral effects are mediated by both local and distal type I interferon responses. Importantly, while a single eTIP1 dose protects animals from SARS-CoV-2 infection, it also stimulates production of SARS-CoV-2 neutralizing antibodies that afford long-lasting protection from SARS-CoV-2 reinfection. Thus, eTIP1 is a safe and effective broad-spectrum antiviral generating short- and long-term protection against SARS-CoV-2 and other respiratory infections in animal models.</AbstractText><CopyrightInformation>Copyright © 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Yinghong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lidsky</LastName><ForeName>Peter V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirogane</LastName><ForeName>Yuta</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aviner</LastName><ForeName>Ranen</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Biology and Genetics, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chien-Ting</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Baxter Laboratory for Stem Cell Biology, Department of Microbiology &amp; Immunology, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Weiyi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Weihao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Dale</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA; Aleph Therapeutics, Inc., Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catching</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doitsh</LastName><ForeName>Gilad</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Weiheng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA; School of Life Sciences, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gekko</LastName><ForeName>Colby E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nayak</LastName><ForeName>Arabinda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Biology and Genetics, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ernst</LastName><ForeName>Joel D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodsky</LastName><ForeName>Leonid</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Tauber Bioinformatics Research Center and Department of Evolutionary &amp; Environmental Biology, University of Haifa, Mount Carmel, Haifa 31905, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodsky</LastName><ForeName>Elia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pine Biotech Inc., New Orleans, LA 70112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>Elsa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Functional Genomics and Cellular Engineering, AI and Cognitive Software, IBM Almaden Research Center, San Jose, CA 95120, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capponi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Functional Genomics and Cellular Engineering, AI and Cognitive Software, IBM Almaden Research Center, San Jose, CA 95120, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bianco</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Functional Genomics and Cellular Engineering, AI and Cognitive Software, IBM Almaden Research Center, San Jose, CA 95120, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Aleph Therapeutics, Inc., Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Peter K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Baxter Laboratory for Stem Cell Biology, Department of Microbiology &amp; Immunology, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frydman</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biology and Genetics, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andino</LastName><ForeName>Raul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: raul.andino@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI127447</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI169460</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI040085</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI144144</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R41 AI155100</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AI036178</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R41 AI157129</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI036178</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000080908">Broadly Neutralizing Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Immunol. 2022 Jan;22(1):5. doi: 10.1038/s41577-021-00668-y</RefSource><PMID Version="1">34862485</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Med. 2022 Jan 14;3(1):1-2. doi: 10.1016/j.medj.2021.12.006</RefSource><PMID Version="1">35590140</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080908" MajorTopicYN="N">Broadly Neutralizing Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089783" MajorTopicYN="N">Defective Interfering Viruses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016679" MajorTopicYN="N">Genome, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RNA viruses</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">broad-spectrum</Keyword><Keyword MajorTopicYN="N">defective viral genomes</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">interferon</Keyword><Keyword MajorTopicYN="N">respiratory infection</Keyword></KeywordList><CoiStatement>Declaration of interests Y.X., R.N., and R. Andino have submitted a patent application. Provisional patent application: recombinant enteroviruses and uses thereof. eTIP1. US Provisional Patent Filed 7/2020. The application was accorded serial no. 63/047,398. D.T. and R.N. are shareholders and employees of Aleph Therapeutics, Inc. E.B. is a shareholder and employee of Pine Biotech Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>1</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34852237</ArticleId><ArticleId IdType="pmc">PMC8598942</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.11.023</ArticleId><ArticleId IdType="pii">S0092-8674(21)01338-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abdool Karim S.S., de Oliveira T. New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. N. Engl. J. Med. 2021;384:1866–1868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008749</ArticleId><ArticleId IdType="pubmed">33761203</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascough S., Vlachantoni I., Kalyan M., Haijema B.-J., Wallin-Weber S., Dijkstra-Tiekstra M., Ahmed M.S., van Roosmalen M., Grimaldi R., Zhang Q., et al. Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial. Am. J. Respir. Crit. Care Med. 2019;200:481–492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6701032</ArticleId><ArticleId IdType="pubmed">30753101</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L., Deng W., Huang B., Gao H., Liu J., Ren L., Wei Q., Yu P., Xu Y., Qi F., et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583:830–833.</Citation><ArticleIdList><ArticleId IdType="pubmed">32380511</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessière P., Wasniewski M., Picard-Meyer E., Servat A., Figueroa T., Foret-Lucas C., Coggon A., Lesellier S., Boué F., Cebron N., et al. Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. PLoS Pathog. 2021;17:e1009427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8376007</ArticleId><ArticleId IdType="pubmed">34370799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohrer A.C., Castro E., Hu Z., Queiroz A.T.L., Tocheny C.E., Assmann M., Sakai S., Nelson C., Baker P.J., Ma H., et al. Tuberculosis Imaging Program Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. J. Exp. Med. 2021;218:e20210469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8348215</ArticleId><ArticleId IdType="pubmed">34347010</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan K., Bowie A.G. Activation of host pattern recognition receptors by viruses. Curr. Opin. Microbiol. 2010;13:503–507.</Citation><ArticleIdList><ArticleId IdType="pubmed">20538506</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrill C.P., Strings V.R., Andino R. Poliovirus: Generation, Quantification, Propagation, Purification, and Storage. Curr. Protoc. Microbiol. 2013 doi: 10.1002/9780471729259.mc15h01s29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780471729259.mc15h01s29</ArticleId><ArticleId IdType="pmc">PMC4826561</ArticleId><ArticleId IdType="pubmed">23686830</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrill C.P., Strings V.R., Schulte M.B., Andino R. Poliovirus: Generation and Characterization of Mutants. Curr. Protoc. Microbiol. 2013 doi: 10.1002/9780471729259.mc15h02s29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780471729259.mc15h02s29</ArticleId><ArticleId IdType="pmc">PMC4826568</ArticleId><ArticleId IdType="pubmed">23686829</ArticleId></ArticleIdList></Reference><Reference><Citation>Canedo-Marroquín G., Saavedra F., Andrade C.A., Berrios R.V., Rodríguez-Guilarte L., Opazo M.C., Riedel C.A., Kalergis A.M. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. Front. Immunol. 2020;11:569760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7759609</ArticleId><ArticleId IdType="pubmed">33362758</ArticleId></ArticleIdList></Reference><Reference><Citation>Caskey M., Lefebvre F., Filali-Mouhim A., Cameron M.J., Goulet J.-P., Haddad E.K., Breton G., Trumpfheller C., Pollak S., Shimeliovich I., et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 2011;208:2357–2366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256967</ArticleId><ArticleId IdType="pubmed">22065672</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar A., Liu J., Martinot A.J., McMahan K., Mercado N.B., Peter L., Tostanoski L.H., Yu J., Maliga Z., Nekorchuk M., et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020;369:812–817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243369</ArticleId><ArticleId IdType="pubmed">32434946</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R., Fehr A.R., Vijay R., Mack M., Zhao J., Meyerholz D.K., Perlman S. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016;19:181–193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752723</ArticleId><ArticleId IdType="pubmed">26867177</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R.E., Winkler E.S., Case J.B., Aziati I.D., Bricker T.L., Joshi A., Darling T.L., Ying B., Errico J.M., Shrihari S., et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature. 2021;596:103–108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8349859</ArticleId><ArticleId IdType="pubmed">34153975</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K.M., Powers L.B., Noonan K.E., Roninson I.B., Levenbook I.S. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc. Natl. Acad. Sci. USA. 1991;88:199–203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50777</ArticleId><ArticleId IdType="pubmed">1846038</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K., Benn C.S., Aaby P., Kottilil S., Gallo R. Can existing live vaccines prevent COVID-19? Science. 2020;368:1187–1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">32527819</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen C., Kleynhans J., Gottberg A., von, McMorrow M.L., Wolter N., Bhiman J.N., Moyes J., Plessis M., du, Carrim M., Buys A., et al. SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-2021. Medrxiv. 2021 doi: 10.1101/2021.07.20.21260855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.20.21260855</ArticleId><ArticleId IdType="pmc">PMC8920516</ArticleId><ArticleId IdType="pubmed">35298900</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier D.A., Ferreira I.A.T.M., Kotagiri P., Datir R.P., Lim E.Y., Touizer E., Meng B., Abdullahi A., Elmer A., Kingston N., et al. CITIID-NIHR BioResource COVID-19 Collaboration Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417–422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373615</ArticleId><ArticleId IdType="pubmed">34192737</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S., Andino R. Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. Microbes Infect. 2002;4:1301–1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">12443894</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S., Cameron C.E., Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. USA. 2001;98:6895–6900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34449</ArticleId><ArticleId IdType="pubmed">11371613</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif D., Hammi I., Kihel A., El Idrissi Saik I., Guessous F., Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb. Pathog. 2021;153:104799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7889464</ArticleId><ArticleId IdType="pubmed">33609650</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng W., Bao L., Liu J., Xiao C., Liu J., Xue J., Lv Q., Qi F., Gao H., Yu P., et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science. 2020;369:818–823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402625</ArticleId><ArticleId IdType="pubmed">32616673</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X., Garcia-Knight M.A., Khalid M.M., Servellita V., Wang C., Morris M.K., Sotomayor-González A., Glasner D.R., Reyes K.R., Gliwa A.S., et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021;184:3426–3437.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8057738</ArticleId><ArticleId IdType="pubmed">33991487</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimmock N.J., Easton A.J. Defective interfering influenza virus RNAs: time to reevaluate their clinical potential as broad-spectrum antivirals? J. Virol. 2014;88:5217–5227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019098</ArticleId><ArticleId IdType="pubmed">24574404</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimmock N.J., Easton A.J. Cloned Defective Interfering Influenza RNA and a Possible Pan-Specific Treatment of Respiratory Virus Diseases. Viruses. 2015;7:3768–3788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517125</ArticleId><ArticleId IdType="pubmed">26184282</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinnon K.H., 3rd, Leist S.R., Schäfer A., Edwards C.E., Martinez D.R., Montgomery S.A., West A., Yount B.L., Jr., Hou Y.J., Adams L.E., et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586:560–566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8034761</ArticleId><ArticleId IdType="pubmed">32854108</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E., Escarmís C., Sevilla N., Moya A., Elena S.F., Quer J., Novella I.S., Holland J.J. Basic concepts in RNA virus evolution. FASEB J. 1996;10:859–864.</Citation><ArticleIdList><ArticleId IdType="pubmed">8666162</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E., Ruiz-Jarabo C.M., Sierra S., Arias A., Pariente N., Baranowski E., Escarmis C. Emergence and selection of RNA virus variants: memory and extinction. Virus Res. 2002;82:39–44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11885948</ArticleId></ArticleIdList></Reference><Reference><Citation>Easton A.J., Scott P.D., Edworthy N.L., Meng B., Marriott A.C., Dimmock N.J. A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo. Vaccine. 2011;29:2777–2784.</Citation><ArticleIdList><ArticleId IdType="pubmed">21320545</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum D.C., June C.H. Cytokine Storm. N. Engl. J. Med. 2020;383:2255–2273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Findlay J.S., Ulaeto D., D’Elia R.V. Cytokines and viral hemorrhagic fever: potential for therapeutic intervention. Future Virology. 2015;5:547–557.</Citation></Reference><Reference><Citation>Finlay B.B., McFadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell. 2006;124:767–782.</Citation><ArticleIdList><ArticleId IdType="pubmed">16497587</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick J.-M., Minogue E., Curham L., Tyrrell H., Gavigan P., Hind W., Downer E.J. MyD88-dependent and -independent signalling via TLR3 and TLR4 are differentially modulated by Δ9-tetrahydrocannabinol and cannabidiol in human macrophages. J. Neuroimmunol. 2020;343:577217.</Citation><ArticleIdList><ArticleId IdType="pubmed">32244040</ArticleId></ArticleIdList></Reference><Reference><Citation>Furio L., Billard H., Valladeau J., Péguet-Navarro J., Berthier-Vergnes O. Poly(I:C)-Treated human langerhans cells promote the differentiation of CD4+ T cells producing IFN-γ and IL-10. J. Invest. Dermatol. 2009;129:1963–1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">19242516</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Sastre A., Egorov A., Matassov D., Brandt S., Levy D.E., Durbin J.E., Palese P., Muster T. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology. 1998;252:324–330.</Citation><ArticleIdList><ArticleId IdType="pubmed">9878611</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller R., Taguwa S., Frydman J. Broad action of Hsp90 as a host chaperone required for viral replication. Biochim. Biophys. Acta. 2012;1823:698–706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339566</ArticleId><ArticleId IdType="pubmed">22154817</ArticleId></ArticleIdList></Reference><Reference><Citation>Genoyer E., López C.B. The Impact of Defective Viruses on Infection and Immunity. Annu. Rev. Virol. 2019;6:547–566.</Citation><ArticleIdList><ArticleId IdType="pubmed">31082310</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilfoy F.D., Mason P.W. West Nile virus-induced interferon production is mediated by the double-stranded RNA-dependent protein kinase PKR. J. Virol. 2007;81:11148–11158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045557</ArticleId><ArticleId IdType="pubmed">17686861</ArticleId></ArticleIdList></Reference><Reference><Citation>Goff P.H., Gao Q., Palese P. A majority of infectious Newcastle disease virus particles contain a single genome, while a minority contain multiple genomes. J. Virol. 2012;86:10852–10856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3457277</ArticleId><ArticleId IdType="pubmed">22787227</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonçalves B.C., Lopes Barbosa M.G., Silva Olak A.P., Belebecha Terezo N., Nishi L., Watanabe M.A., Marinello P., Zendrini Rechenchoski D., Dejato Rocha S.P., Faccin-Galhardi L.C. Antiviral therapies: advances and perspectives. Fundam. Clin. Pharmacol. 2021;35:305–320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675511</ArticleId><ArticleId IdType="pubmed">33011993</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.-Q., Wang Y., Teng Y., Zhao Z., Cui Y., et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020;369:1603–1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7574913</ArticleId><ArticleId IdType="pubmed">32732280</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo K., Barrett B.S., Mickens K.L., Hasenkrug K.J., Santiago M.L. Interferon Resistance of Emerging SARS-CoV-2 Variants. BioRxiv. 2021 doi: 10.1101/2021.03.20.436257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.20.436257</ArticleId><ArticleId IdType="pmc">PMC9371743</ArticleId><ArticleId IdType="pubmed">35867811</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta V., Bhoyar R.C., Jain A., Srivastava S., Upadhayay R., Imran M., Jolly B., Divakar M.K., Sharma D., Sehgal P., et al. Asymptomatic Reinfection in 2 Healthcare Workers From India With Genetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2. Clin. Infect. Dis. 2020;73:e2823–e2825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543380</ArticleId><ArticleId IdType="pubmed">32964927</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoagland D.A., Møller R., Uhl S.A., Oishi K., Frere J., Golynker I., Horiuchi S., Panis M., Blanco-Melo D., Sachs D., et al. Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity. 2021;54:557–570.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7846242</ArticleId><ArticleId IdType="pubmed">33577760</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang A.S., Baltimore D. Defective viral particles and viral disease processes. Nature. 1970;226:325–327.</Citation><ArticleIdList><ArticleId IdType="pubmed">5439728</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q., Ji K., Tian S., Wang F., Huang B., Tong Z., Tan S., Hao J., Wang Q., Tan W., et al. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nat. Commun. 2021;12:776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7858593</ArticleId><ArticleId IdType="pubmed">33536425</ArticleId></ArticleIdList></Reference><Reference><Citation>Ida-Hosonuma M., Iwasaki T., Yoshikawa T., Nagata N., Sato Y., Sata T., Yoneyama M., Fujita T., Taya C., Yonekawa H., Koike S. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J. Virol. 2005;79:4460–4469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1061561</ArticleId><ArticleId IdType="pubmed">15767446</ArticleId></ArticleIdList></Reference><Reference><Citation>Jangra S., De Vrieze J., Choi A., Rathnasinghe R., Laghlali G., Uvyn A., Van Herck S., Nuhn L., Deswarte K., Zhong Z., et al. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine∗. Angew. Chem. Int. Ed. Engl. 2021;60:9467–9473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014308</ArticleId><ArticleId IdType="pubmed">33464672</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang R.-D., Liu M.-Q., Chen Y., Shan C., Zhou Y.-W., Shen X.-R., Li Q., Zhang L., Zhu Y., Si H.-R., et al. Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2. Cell. 2020;182:50–58.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241398</ArticleId><ArticleId IdType="pubmed">32516571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang L., He G., Sharp A.K., Wang X., Brown A.M., Michalak P., Weger-Lucarelli J. A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation. Cell. 2021;184:4392–4400.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260498</ArticleId><ArticleId IdType="pubmed">34289344</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikkert M. Innate Immune Evasion by Human Respiratory RNA Viruses. J. Innate Immun. 2020;12:4–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6959104</ArticleId><ArticleId IdType="pubmed">31610541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.H., Narayanan K., Makino S. Characterization of coronavirus DI RNA packaging. Adv. Exp. Med. Biol. 1998;440:347–353.</Citation><ArticleIdList><ArticleId IdType="pubmed">9782302</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura N., Semler B.L., Rothberg P.G., Larsen G.R., Adler C.J., Dorner A.J., Emini E.A., Hanecak R., Lee J.J., van der Werf S., et al. Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature. 1981;291:547–553.</Citation><ArticleIdList><ArticleId IdType="pubmed">6264310</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka-Anstadt J.L., Campagnoli R., Vincent A., Shaw J., Wei L., Wynn N.T., Smithee S.E., Bujaki E., Te Yeh M., Laassri M., et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020;5:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>Konz J.O., Schofield T., Carlyle S., Wahid R., Ansari A., Strating J.R.P.M., Yeh M.T., Manukyan H., Smits S.L., Tritama E., et al. Evaluation and validation of next-generation sequencing to support lot release for a novel type 2 oral poliovirus vaccine. Vaccine X. 2021;8:100102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233139</ArticleId><ArticleId IdType="pubmed">34195600</ArticleId></ArticleIdList></Reference><Reference><Citation>Kranz L.M., Diken M., Haas H., Kreiter S., Loquai C., Reuter K.C., Meng M., Fritz D., Vascotto F., Hefesha H., et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396–401.</Citation><ArticleIdList><ArticleId IdType="pubmed">27281205</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi L.I., Rezelj V.V., Henrion-Lacritick A., Erazo D., Boussier J., Vallet T., Bernhauerová V., Suzuki Y., Carrau L., Weger-Lucarelli J., et al. Defective viral genomes from chikungunya virus are broad-spectrum antivirals and prevent virus dissemination in mosquitoes. PLoS Pathog. 2021;17:e1009110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7870000</ArticleId><ArticleId IdType="pubmed">33556143</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Wei J., Yang F., Liu H.-N., Zhu Z.-X., Cao W.-J., Li S., Liu X.-T., Zheng H.-X., Shu H.-B. Foot-and-mouth disease virus structural protein VP3 degrades Janus kinase 1 to inhibit IFN-γ signal transduction pathways. Cell Cycle. 2016;15:850–860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4845950</ArticleId><ArticleId IdType="pubmed">26901336</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Yang W., Yang F., Liu H., Zhu Z., Lian K., Lei C., Li S., Liu X., Zheng H., Shu H. The VP3 structural protein of foot-and-mouth disease virus inhibits the IFN-β signaling pathway. FASEB J. 2016;30:1757–1766.</Citation><ArticleIdList><ArticleId IdType="pubmed">26813975</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundstrom K. Coronavirus Pandemic-Therapy and Vaccines. Biomedicines. 2020;8:109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7277397</ArticleId><ArticleId IdType="pubmed">32375268</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutrick K., Ellingson K.D., Baccam Z., Rivers P., Beitel S., Parker J., Hollister J., Sun X., Gerald J.K., Komatsu K., et al. COVID-19 Infection, Reinfection, and Vaccine Effectiveness in a Prospective Cohort of Arizona Frontline/Essential Workers: The AZ HEROES Research Protocol. JMIR Res Protoc. 2021;10:e28925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8386365</ArticleId><ArticleId IdType="pubmed">34057904</ArticleId></ArticleIdList></Reference><Reference><Citation>McClure M.A., Holland J.J., Perrault J. Generation of defective interfering particles in picornaviruses. Virology. 1980;100:408–418.</Citation><ArticleIdList><ArticleId IdType="pubmed">6243434</ArticleId></ArticleIdList></Reference><Reference><Citation>Meganck R.M., Baric R.S. Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nat. Med. 2021;27:401–410.</Citation><ArticleIdList><ArticleId IdType="pubmed">33723456</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerholz D.K., Beck A.P. Histopathologic Evaluation and Scoring of Viral Lung Infection. Methods Mol. Biol. 2020;2099:205–220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7123785</ArticleId><ArticleId IdType="pubmed">31883098</ArticleId></ArticleIdList></Reference><Reference><Citation>Murillo-Zamora E., Mendoza-Cano O., Delgado-Enciso I., Hernandez-Suarez C.M. Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection. Public Health. 2021;193:113–115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7879028</ArticleId><ArticleId IdType="pubmed">33774512</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan, K., and Makino, S. (2009). Coronaviruses and arteriviruses. In Cellular Signaling and Innate Immune Responses to RNA Virus Infections. A.R. Brasier, A. García-Sastre, S.M. Lemon, eds. (ASM Press). pp. 373–387.</Citation></Reference><Reference><Citation>Nagata N., Iwasaki T., Ami Y., Sato Y., Hatano I., Harashima A., Suzaki Y., Yoshii T., Hashikawa T., Sata T., et al. A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21. Virology. 2004;321:87–100.</Citation><ArticleIdList><ArticleId IdType="pubmed">15033568</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelemans T., Kikkert M. Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections. Viruses. 2019;11:961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6832425</ArticleId><ArticleId IdType="pubmed">31635238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohka S., Igarashi H., Nagata N., Sakai M., Koike S., Nochi T., Kiyono H., Nomoto A. Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J. Virol. 2007;81:7902–7912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951287</ArticleId><ArticleId IdType="pubmed">17507470</ArticleId></ArticleIdList></Reference><Reference><Citation>Palese P. 128 Toward a Universal Influenza Virus Vaccine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2012;59:53.</Citation></Reference><Reference><Citation>Peersen O.B. Picornaviral polymerase structure, function, and fidelity modulation. Virus Res. 2017;234:4–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5476519</ArticleId><ArticleId IdType="pubmed">28163093</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrault J. Current Topics in Microbiology and Immunology: Initiation Signals in Viral Gene Expression. Springer; 1981. Origin and Replication of Defective Interfering Particles; pp. 151–207.</Citation><ArticleIdList><ArticleId IdType="pubmed">7026180</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrault J., Semler B.L. Internal genome deletions in two distinct classes of defective interfering particles of vesicular stomatitis virus. Proc. Natl. Acad. Sci. USA. 1979;76:6191–6195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC411829</ArticleId><ArticleId IdType="pubmed">230501</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer J.K. Innate host barriers to viral trafficking and population diversity: lessons learned from poliovirus. Adv. Virus Res. 2010;77:85–118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234684</ArticleId><ArticleId IdType="pubmed">20951871</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer J.K., Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. USA. 2003;100:7289–7294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165868</ArticleId><ArticleId IdType="pubmed">12754380</ArticleId></ArticleIdList></Reference><Reference><Citation>Preissner K.T., Fischer S., Deindl E. Extracellular RNA as a Versatile DAMP and Alarm Signal That Influences Leukocyte Recruitment in Inflammation and Infection. Front. Cell Dev. Biol. 2020;8:619221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7775424</ArticleId><ArticleId IdType="pubmed">33392206</ArticleId></ArticleIdList></Reference><Reference><Citation>Que Y., Hu C., Wan K., Hu P., Wang R., Luo J., Li T., Ping R., Hu Q., Sun Y., et al. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int. Rev. Immunol. 2021 doi: 10.1080/08830185.2021.1884248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08830185.2021.1884248</ArticleId><ArticleId IdType="pmc">PMC7919105</ArticleId><ArticleId IdType="pubmed">33616462</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahim M.M.A., Parsons B.D., Price E.L., Slaine P.D., Chilvers B.L., Seaton G.S., Wight A., Medina-Luna D., Dey S., Grandy S.L., et al. Defective Influenza A Virus RNA Products Mediate MAVS-Dependent Upregulation of Human Leukocyte Antigen Class I Proteins. J. Virol. 2020;94 e00165-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307169</ArticleId><ArticleId IdType="pubmed">32321802</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappazzo C.G., Tse L.V., Kaku C.I., Wrapp D., Sakharkar M., Huang D., Deveau L.M., Yockachonis T.J., Herbert A.S., Battles M.B., et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021;371:823–829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963221</ArticleId><ArticleId IdType="pubmed">33495307</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathnasinghe R., Salvatore M., Zheng H., Jangra S., Kehrer T., Mena I., Schotsaert M., Muster T., Palese P., García-Sastre A. Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine. BioRxiv. 2021 doi: 10.1101/2021.04.28.441797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.28.441797</ArticleId><ArticleId IdType="pmc">PMC8589955</ArticleId><ArticleId IdType="pubmed">34773048</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezelj V.V., Carrau L., Merwaiss F., Levi L.I., Erazo D., Tran Q.D., Henrion-Lacritick A., Gausson V., Suzuki Y., Shengjuler D., et al. Defective viral genomes as therapeutic interfering particles against flavivirus infection in mammalian and mosquito hosts. Nat. Commun. 2021;12:2290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8052367</ArticleId><ArticleId IdType="pubmed">33863888</ArticleId></ArticleIdList></Reference><Reference><Citation>Samarasinghe A.E., Woolard S.N., Boyd K.L., Hoselton S.A., Schuh J.M., McCullers J.A. The immune profile associated with acute allergic asthma accelerates clearance of influenza virus. Immunol. Cell Biol. 2014;92:449–459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4037497</ArticleId><ArticleId IdType="pubmed">24469764</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheideler M., Vidakovic I., Prassl R. Lipid nanocarriers for microRNA delivery. Chem. Phys. Lipids. 2020;226:104837.</Citation><ArticleIdList><ArticleId IdType="pubmed">31689410</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins J.W., Rice C.M. Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 2011;1:519–525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3274382</ArticleId><ArticleId IdType="pubmed">22328912</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., Rice C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472:481–485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409588</ArticleId><ArticleId IdType="pubmed">21478870</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins J.W., MacDuff D.A., Imanaka N., Gainey M.D., Shrestha B., Eitson J.L., Mar K.B., Richardson R.B., Ratushny A.V., Litvak V., et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature. 2014;505:691–695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4077721</ArticleId><ArticleId IdType="pubmed">24284630</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefik E., Israelow B., Zhao J., Qu R., Song E., Mirza H., Kaffe E., Halene S., Meffre E., Kluger Y., et al. Res Square; 2021. A humanized mouse model of chronic COVID-19 to evaluate disease mechanisms and treatment options.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9203605</ArticleId><ArticleId IdType="pubmed">34921308</ArticleId></ArticleIdList></Reference><Reference><Citation>Semler B.L., Perrault J., Abelson J., Holland J.J. Sequence of a RNA templated by the 3′-OH RNA terminus of defective interfering particles of vesicular stomatitis virus. Proc. Natl. Acad. Sci. USA. 1978;75:4704–4708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC336188</ArticleId><ArticleId IdType="pubmed">216996</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirogane Y., Rousseau E., Voznica J., Rouzine I.M., Bianco S., Andino R. Experimental and mathematical insights on the competition between poliovirus and a defective interfering genome. bioRxiv. 2019 doi: 10.1101/519751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/519751</ArticleId><ArticleId IdType="pmc">PMC8496841</ArticleId><ArticleId IdType="pubmed">34570820</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirogane Y., Rousseau E., Voznica J., Xiao Y., Su W., Catching A., Whitfield Z.J., Rouzine I.M., Bianco S., Andino R. Experimental and mathematical insights on the interactions between poliovirus and a defective interfering genome. BioRxiv. 2021 doi: 10.1101/2021.01.11.426198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.11.426198</ArticleId><ArticleId IdType="pmc">PMC8496841</ArticleId><ArticleId IdType="pubmed">34570820</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirogane Y., Rousseau E., Voznica J., Xiao Y., Su W., Catching A., Whitfield Z.J., Rouzine I.M., Bianco S., Andino R. Experimental and mathematical insights on the interactions between poliovirus and a defective interfering genome. PLoS Pathog. 2021;17:e1009277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8496841</ArticleId><ArticleId IdType="pubmed">34570820</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S.-H., Chen Q., Gu H.-J., Yang G., Wang Y.-X., Huang X.-Y., Liu S.-S., Zhang N.-N., Li X.-F., Xiong R., et al. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. Cell Host Microbe. 2020;28:124–133.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250783</ArticleId><ArticleId IdType="pubmed">32485164</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z., Kim A., Sobolewski M.D., Enick N., Chen C., Adams C., Jacobs J.L., McCormick K.D., Mellors J.W., Dimitrov D.S., Li W. Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains. BioRxiv. 2021 doi: 10.1101/2021.03.22.436481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.22.436481</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C., Roberts A., Goff L., Pertea G., Kim D., Kelley D.R., Pimentel H., Salzberg S.L., Rinn J.L., Pachter L. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 2012;7:562–578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334321</ArticleId><ArticleId IdType="pubmed">22383036</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse L.V., Meganck R.M., Graham R.L., Baric R.S. The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses. Front. Microbiol. 2020;11:658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7193113</ArticleId><ArticleId IdType="pubmed">32390971</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., De Coster I., Bandyopadhyay A.S., Revets H., Withanage K., De Smedt P., Suykens L., Oberste M.S., Weldon W.C., Costa-Clemens S.A., et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394:148–158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignuzzi M., López C.B. Defective viral genomes are key drivers of the virus-host interaction. Nat. Microbiol. 2019;4:1075–1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097797</ArticleId><ArticleId IdType="pubmed">31160826</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Li W., Drabek D., Okba N.M.A., van Haperen R., Osterhaus A.D.M.E., van Kuppeveld F.J.M., Haagmans B.L., Grosveld F., Bosch B.-J. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 2020;11:2251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198537</ArticleId><ArticleId IdType="pubmed">32366817</ArticleId></ArticleIdList></Reference><Reference><Citation>White K.M., Rosales R., Yildiz S., Kehrer T., Miorin L., Moreno E., Jangra S., Uccellini M.B., Rathnasinghe R., Coughlan L. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science. 2021;371:926–931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963220</ArticleId><ArticleId IdType="pubmed">33495306</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  . 2021. Coronavirus diseas (COVID-19)https://www.who.int/health-topics/coronavirus#tab=tab_1</Citation></Reference><Reference><Citation>Winkler E.S., Bailey A.L., Kafai N.M., Nair S., McCune B.T., Yu J., Fox J.M., Chen R.E., Earnest J.T., Keeler S.P., et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 2020;21:1327–1335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578095</ArticleId><ArticleId IdType="pubmed">32839612</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Dolan P.T., Goldstein E.F., Li M., Farkov M., Brodsky L., Andino R. Poliovirus intrahost evolution is required to overcome tissue-specific innate immune responses. Nat. Commun. 2017;8:375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5575128</ArticleId><ArticleId IdType="pubmed">28851882</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh M.T., Bujaki E., Dolan P.T., Smith M., Wahid R., Konz J., Weiner A.J., Bandyopadhyay A.S., Van Damme P., De Coster I., et al. Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host Microbe. 2020;27:736–751.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Wang J., Muñoz-Moreno R., Kim M., Sakthivel R., Mo W., Shao D., Anantharaman A., García-Sastre A., Conrad N.K., et al. Influenza Virus NS1 Protein RNA-Interactome Reveals Intron Targeting. J. Virol. 2018;92 e01634-18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6258958</ArticleId><ArticleId IdType="pubmed">30258002</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Jiang S.-C., Zhang Z.-W., Fu Y.-F., Hu J., Li Z.-L. Quantification of Cytokine Storms During Virus Infections. Front. Immunol. 2021;12:659419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8165266</ArticleId><ArticleId IdType="pubmed">34079547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Ding N., Song Y., Song R., Pan Y., Wang L., Yan S., Wang Q., Ma S., Wei L., et al. Phylogenomic tracing of asymptomatic transmission in a COVID-19 outbreak. Innovation. 2021;2:100099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7982642</ArticleId><ArticleId IdType="pubmed">33778799</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B., Thao T.T.N., Hoffmann D., Taddeo A., Ebert N., Labroussaa F., Pohlmann A., King J., Steiner S., Kelly J.N., et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature. 2021;592:122–127.</Citation><ArticleIdList><ArticleId IdType="pubmed">33636719</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. China Novel Coronavirus Investigating and Research Team A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>